Continued Rebound: Trends in Life Science M&A
0 likes1,338 views
This document provides an overview and analysis of trends in life science mergers and acquisitions from 2005 to 2011. It analyzes big exits, investments by indication for biotech and medical devices, and indication performance. The first part reviews annual big exits, total exit value, average time to exit, and deal structures. Biotech saw more structured deals while devices saw more outright acquisitions. Later sections analyze investments and exits by clinical indication for biotech and devices.
Continued Rebound: Trends in Life Science M&A
- 1. Continued Rebound: Trends in Life Science M&A Silicon Valley Bank July 2012 Written By: y Jonathan Norris Managing Director 650.926.0126 jnorris@svb.com 1
- 2. Agenda • Part I:Overview of 2011 Big Exits • Part II: Analysis by Indication o Series A Investment by Indication between 2005 and 2011 o LPI and Hit Rate – Measuring Indication Performance in the Life Science Industry 2
- 3. Overview of Big Exits 3
- 4. M&A Big Exits Per Year ( g (2005-2011) ) 4
- 5. Total Big Exit Dollar Volume g 5
- 6. Average Time to Exit g 6
- 7. Biotech Deal Type yp 7
- 8. Biotech Big Exits g 8
- 9. Biotech Structured Deal Breakdown 9
- 10. Biotech Breakdown by Stage, Round, Years to Exit y g , , 10
- 11. Biotech Upfront Payments by Stage in Structured Deal Era (2009-2011) ( ) 11
- 12. Device Big Exits g 12
- 13. Device Structured Deal Breakdown 13
- 14. Device Stage Breakdown g 14
- 15. Device Capital Efficient Exits by Multiple p y p 15
- 16. Analysis By Indication y y 16
- 17. Life Science Series A Data 17
- 18. Biotech Series A Data 18
- 19. Device Series A Data 19
- 20. Life Science Investments by Indication y 20
- 22. Indication Breakdown: Med Device 22
- 23. Biotech Indication Performance Data 23
- 24. Device Indication Performance Data 24
- 25. Disclosures This material, including without limitation the statistical information herein, is provided for informational purposes only. The material is based in part upon information from third-party only sources that we believe to be reliable, but which has not been independently verified by us and, as such, we do not represent that the information is accurate or complete. The information should not be viewed as tax, investment, legal or other advice nor is it to be relied on in making an investment or other decision. You should obtain relevant and specific professional advice b f f i l d i before making any i ki investment d i i t t decision. N thi relating t th material Nothing l ti to the t i l should be construed as a solicitation or offer, or recommendation, to acquire or dispose of any investment or to engage in any other transaction. U.S. VC-backed Service companies were included under the device category. Services represented l t d less th 10 percent of all d l i thi category. R ti than t f ll deals in this t Rational f i l di l for including Services was to try and capture as much U.S. LS Venture investment as possible - creating an additional category with a small data set did not make sense. ©2012 SVB Financial Group All rights reserved Member Federal Reserve System Group. reserved. System. SVB>, SVB>Find a way, SVB Financial Group, and Silicon Valley Bank are registered trademarks. B-12-12265. Rev. 07-16-12. 25